Specialty Pharmacy

Nonalcoholic steatohepatitis or NASH is a form of Nonalcoholic fatty liver disease or NAFLD, in which the liver is inflamed and damaged due to the buildup of fat in the liver.

AMCP student webinar that described the characteristics of specialty medications and some of the unique aspects of this category, including a discussion on biosimilars, benefit design challenges, and introductory specialty channel management.

AMCP student webinar that described the characteristics of specialty medications and some of the unique aspects of this category, including a discussion on biosimilars, benefit design challenges, and introductory specialty channel management.

AMCP webinar that reviewed proceedings from this Partnership Forum.

JMCP has added two prominent academic health care researchers to its editorial team, a move designed to keep pace with the growing influence of AMCP’s peer-reviewed, scientific journal.

Partnership Forum: This forum made recommendations and considerations for ways that benefit design and reimbursement may evolve without compromising patient access and care.

Increased simplicity, broader financial risk sharing, and an enhanced focus on patient care were among the recommendations developed by diverse stakeholders at a recent AMCP Partnership Forum focused on how to better manage the high costs of specialty medications.

From the AMCP Policy Digest, AMCP's policies regarding specialty pharmacy and biosimilars

Disease management is the concept of reducing health care costs and improving quality of life for individuals with chronic conditions by preventing or minimizing the effects of the disease through integrated care. Disease management programs are designed to improve the health of persons with chronic conditions and reduce associated costs from avoidable complications by identifying and treating chronic conditions more quickly and more effectively, thus slowing the progression of those diseases.

Over the past several years, the introduction, utilization and cost share of specialty pharmacy products has been increasing at a rate substantially greater than that of other pharmaceuticals. This paper examines the characteristics of specialty pharmaceuticals; the growth of new expertise to handle and manage these pharmaceuticals; and the needs these products create for patients, health plans and practitioners.

Press Release: From News&Views April 2019: The Biologics Price Competition and Innovation Act (BPCIA) of 2009 created an FDA approval pathway for biosimilars that aimed to expanded patient access to these more affordable therapies.